CN104784102B - 头孢替唑钠软膏 - Google Patents
头孢替唑钠软膏 Download PDFInfo
- Publication number
- CN104784102B CN104784102B CN201510123101.2A CN201510123101A CN104784102B CN 104784102 B CN104784102 B CN 104784102B CN 201510123101 A CN201510123101 A CN 201510123101A CN 104784102 B CN104784102 B CN 104784102B
- Authority
- CN
- China
- Prior art keywords
- ointment
- weight
- sodium
- composition
- cefobutazine sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 62
- 239000011734 sodium Substances 0.000 title claims abstract description 62
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 62
- 239000002674 ointment Substances 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 claims abstract description 39
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical group OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims abstract description 14
- PXDJXZJSCPSGGI-UHFFFAOYSA-N palmityl palmitate Chemical group CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-methyl-pyrrolidinone Natural products CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 13
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 12
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 12
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 11
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 11
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 11
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 11
- 239000005642 Oleic acid Substances 0.000 claims description 11
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 11
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 11
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 11
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- HVUMOYIDDBPOLL-UHFFFAOYSA-N 2-(3,4-Dihydroxyoxolan-2-yl)-2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)C1OCC(O)C1O HVUMOYIDDBPOLL-UHFFFAOYSA-N 0.000 abstract description 11
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 abstract description 10
- 239000011159 matrix material Substances 0.000 abstract description 6
- 239000003961 penetration enhancing agent Substances 0.000 abstract description 6
- 239000003883 ointment base Substances 0.000 abstract description 4
- 239000003755 preservative agent Substances 0.000 abstract description 3
- 230000002335 preservative effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 32
- 210000003491 skin Anatomy 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 240000001307 Myosotis scorpioides Species 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000003851 azoles Chemical class 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- DZMVCVMFETWNIU-LDYMZIIASA-N ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 description 5
- 229960004366 ceftezole Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000013271 transdermal drug delivery Methods 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 150000004869 1,3,4-thiadiazoles Chemical class 0.000 description 1
- -1 1H-tetrazol-1-ylacetyl Chemical group 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SCABUMPFWJSUED-UHFFFAOYSA-N [Na].CC(=CCCCCC)C(=O)O Chemical compound [Na].CC(=CCCCCC)C(=O)O SCABUMPFWJSUED-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical group CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical group CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 变化情况 |
实施例1 | - |
对比实施例1 | 棕榈酸鲸蜡醇酯、十八醇和司盘60三者的重量比例为1:1:1 |
对比实施例2 | 十二烷基硫酸钠和聚乙二醇3350二者的重量比例为1:1 |
对比实施例3 | 5-甲基吡咯酮、油酸和月桂醇硫酸钠三者的重量比例为1:1:1 |
对比实施例4 | 仅采用棕榈酸鲸蜡醇酯作为油性基质 |
对比实施例5 | 仅采用十二烷基硫酸钠作为水性基质 |
对比实施例6 | 仅采用5-甲基吡咯酮作为渗透促进剂 |
对比实施例7 | 各成分用量发生变化 |
对比实施例8 | 油性基质、水性基质和渗透促进剂辅料均发生变化 |
组别 | 累计透过量% | 角质层滞留量(μg) | 深部皮肤滞留量(μg) |
实施例1 | 未检出 | 23.36±0.16 | 27.15±0.16 |
对比实施例1 | 2.34 | 6.74±0.13 | 4.26±0.27 |
对比实施例2 | 2.10 | 5.65±0.17 | 5.13±0.22 |
对比实施例3 | 1.16 | 4.21±0.20 | 5.32±0.16 |
对比实施例4 | 1.17 | 6.10±0.22 | 5.14±0.18 |
对比实施例5 | 2.37 | 3.75±0.23 | 5.03±0.26 |
对比实施例6 | 2.11 | 3.88±0.15 | 4.23±0.16 |
对比实施例7 | 2.83 | 3.21±0.22 | 4.26±0.15 |
对比实施例8 | 3.22 | 4.33±0.14 | 3.85±0.24 |
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510123101.2A CN104784102B (zh) | 2015-03-20 | 2015-03-20 | 头孢替唑钠软膏 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510123101.2A CN104784102B (zh) | 2015-03-20 | 2015-03-20 | 头孢替唑钠软膏 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104784102A CN104784102A (zh) | 2015-07-22 |
CN104784102B true CN104784102B (zh) | 2018-01-02 |
Family
ID=53549610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510123101.2A Active CN104784102B (zh) | 2015-03-20 | 2015-03-20 | 头孢替唑钠软膏 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104784102B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114028325B (zh) * | 2021-12-10 | 2023-08-01 | 福元药业有限公司 | 一种他克莫司软膏制剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1443532A (zh) * | 2003-04-17 | 2003-09-24 | 中国人民解放军第二军医大学 | 氟比洛芬巴布剂及其制备方法 |
CN101780044A (zh) * | 2009-01-16 | 2010-07-21 | 海南中化联合制药工业有限公司 | 注射用头孢替唑钠粉针制剂及制备方法 |
CN102114026A (zh) * | 2009-12-31 | 2011-07-06 | 天津瑞普生物技术股份有限公司 | 一种治疗鸭腿病的软膏制剂及其制备方法 |
CN104188895A (zh) * | 2014-08-15 | 2014-12-10 | 四川兴科蓉药业有限责任公司 | 甲砜霉素软膏 |
-
2015
- 2015-03-20 CN CN201510123101.2A patent/CN104784102B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1443532A (zh) * | 2003-04-17 | 2003-09-24 | 中国人民解放军第二军医大学 | 氟比洛芬巴布剂及其制备方法 |
CN101780044A (zh) * | 2009-01-16 | 2010-07-21 | 海南中化联合制药工业有限公司 | 注射用头孢替唑钠粉针制剂及制备方法 |
CN102114026A (zh) * | 2009-12-31 | 2011-07-06 | 天津瑞普生物技术股份有限公司 | 一种治疗鸭腿病的软膏制剂及其制备方法 |
CN104188895A (zh) * | 2014-08-15 | 2014-12-10 | 四川兴科蓉药业有限责任公司 | 甲砜霉素软膏 |
Also Published As
Publication number | Publication date |
---|---|
CN104784102A (zh) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1028727B1 (en) | Skin penetration enhancing components | |
EP2266626B1 (en) | Composition for external application comprising transcription factor decoy as active ingredient | |
CN103239391B (zh) | 一种他克莫司软膏 | |
CN112587593B (zh) | 一种治疗痤疮的组合物及其制备方法 | |
JP2002526407A (ja) | フルボ酸、および種々の状態の処置におけるその使用 | |
CN102245188A (zh) | 用于预防和治疗皮肤病学疾病/粘膜疾病的组合物及其用途 | |
CN105431154A (zh) | 抗菌成分 | |
CN104784102B (zh) | 头孢替唑钠软膏 | |
JP6507180B2 (ja) | ボルドおよびセイヨウナツユキソウエキスを含む動物向けの局所組成物およびその使用 | |
CN102657602A (zh) | 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法 | |
CN104688721A (zh) | 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法 | |
CN105456182A (zh) | 一种治疗真菌感染的外用乳膏及其生产方法 | |
RU2481834C2 (ru) | Антимикробная композиция для лечения ран и ожогов | |
CN104224802B (zh) | 一种盐酸莫西沙星滴耳剂及其制备方法 | |
PT2079441E (pt) | Composição antibiótica tópica para a prevenção da doença de lyme | |
US10272039B2 (en) | Topical sodium nitrite formulation | |
CN103897010A (zh) | 一种用于治疗银屑病的组合物及制备方法 | |
CN104188895B (zh) | 甲砜霉素软膏 | |
ES2549045T3 (es) | Método para tratar una infección por el virus del herpes usando un compuesto de lactona macrocíclica | |
WO2009091291A1 (fr) | Sel d'argent de n-(6-méthyl-2,4-dioxo-1,2,3,4-tétrahydro-5h-pyrimidinesulfone)-isonicotinoyl hydrazide | |
CN104840404A (zh) | 一种具有除臭功能的化妆品及其制备方法 | |
JP3827259B2 (ja) | 表皮角質化促進剤 | |
RU2519085C1 (ru) | Противопаразитарное средство для сельскохозяйственных животных | |
CN103127136A (zh) | 一种含有醋丙甲泼尼龙和氨基酸的皮肤药物组合物 | |
US20130273187A1 (en) | Method of treating acne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Song Yixing Inventor before: Liu Ying |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20171205 Address after: Maternal and Child Health Hospital of Zibo No. 11 Zhangdian District of Shandong city of Zibo province Xingyuan road 255000 Applicant after: Song Yixing Address before: 610000 Sichuan city of Chengdu province high tech Zone Kyrgyzstan Road No. 666 Building 2 floor 13 No. 2 Applicant before: Chengdu Hui Zhi distant view Science and Technology Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200714 Address after: 650032 seven kilometers in the western suburb of Wuhua District, Kunming City, Yunnan Province Patentee after: KUNMING BAKER NORTON PHARMACEUTICAL Co.,Ltd. Address before: Maternal and Child Health Hospital of Zibo No. 11 Zhangdian District of Shandong city of Zibo province Xingyuan road 255000 Patentee before: Song Yixing |
|
TR01 | Transfer of patent right |